国际站：Zolbetuximab

CAS：1496553-00-4

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性： Zolbetuximab (IMAB362) 是一种靶向Claudin-18.2 的单克隆抗体。 Zolbetuximab 通过免疫效应机制介导 Claudin-18.2 阳性细胞的特异性杀伤。 Zolbetuximab可用于胃肠道腺癌和胰腺肿瘤的研究^[1]。

体外：Zolbetuximab (0-100 μg/mL) 与 CLDN18.2+ PC 细胞结合，诱导抗体依赖性细胞毒性 (ADCC) 和补体依赖性细胞毒性 (CDC)[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内：单独使用 Zolbetuximab (200 μg，静脉注射) 以及与 Gemcitabine (HY-17026) (50 mg/kg，腹腔注射) 联合使用，在小鼠 BxPC-3-CLDN18.2 异种移植模型中表现出抗肿瘤活性[2]。 Zolbetuximab (5.7 mg/kg，腹腔注射，每周 3 次，持续五周) 抑制 SNU-620 细胞异种移植模型中的肿瘤生长[3]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: mouse BxPC-3-CLDN18.2, MIA PaCa-2-CLDN18.2 xenograft model[2] Dosage: 200 μg alone or with 50 mg/kg Gemcitabine Administration: i.v.; i.p. (Gemcitabine) Result: Inhibited tumor growth in two models, and prevented lung metastasis formation. Prolonged survival time, and lowered fractions of CLDN18.2+ cells in MIA PaCa-2-CLDN18.2 xenograft. Clinical Trial

参考文献：[1]. Kyuno D, et, al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers. 2022 Jan 2;10(1):1967080.

[2]. Türeci Ӧ, et al. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology. 2018 Nov 10;8(1):e1523096.

  [3]. Zhong W, et al. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers. Front Immunol. 2022 Jun 28;13:885424.